Skip to main content
logo
Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.9194
+0.0340 (3.84%)
At close: Aug 20, 2026, 4:00 PM EDT
0.9194
0.00 (0.00%)
After-hours: Aug 20, 2026, 4:35 PM EDT

Akebia Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-29.67-5.35-69.41-51.93-94.23-282.02
Depreciation & Amortization
1.551.2737.537.6337.737.97
Loss (Gain) From Sale of Assets
--0.17----
Asset Writedown & Restructuring Costs
0.06--0.788.77-
Loss (Gain) From Sale of Investments
------0.02
Stock-Based Compensation
13.3111.287.789.3217.8522.74
Provision & Write-off of Bad Debts
0.721.480.88---
Other Operating Activities
35.2543.0122.271.54-41.873.98
Change in Accounts Receivable
18.59-14.144.050.9911.3-24.03
Change in Inventory
-13.71-23.13-28.4-2.5419.09-24.95
Change in Accounts Payable
-3.63.08-1.36-5.241.5-11.74
Change in Unearned Revenue
0.642.68--3.744.651.82
Change in Other Net Operating Assets
18.4247.98-13.96-10.2-37.98-46.72
Operating Cash Flow
41.5567.99-40.66-23.38-73.15-252.97
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1.29-0.29-0.03--0.11-0.06
Sale of Property, Plant & Equipment
-0.17----
Sale (Purchase) of Intangibles
-10.81-7.81----
Investment in Securities
-----40
Investing Cash Flow
-12.1-7.93-0.03--0.1139.94

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-1045---
Long-Term Debt Repaid
--4.23-37.1-32-33-
Net Debt Issued (Repaid)
-5.855.777.9-32-33-
Issuance of Common Stock
4.6568.3643.036.797.688.95
Other Financing Activities
-10-1.21-1.27-4044.78
Financing Cash Flow
-11.272.9349.66-25.2114.6133.73

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
18.26132.998.97-48.59-58.67-79.29

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
40.2667.7-40.69-23.38-73.27-253.02
Free Cash Flow Growth
------
Free Cash Flow Margin
18.38%28.66%-25.40%-12.02%-25.05%-119.55%
Free Cash Flow Per Share
0.150.26-0.19-0.13-0.40-1.52
Levered Free Cash Flow
33.6268.6113.6317.9-15.3-136.04
Unlevered Free Cash Flow
44.4583.732521.67-5.5-123.53

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
6.086.085.046.066.769.63
Change in Working Capital
20.3316.47-39.68-20.73-1.44-105.61
SEC Filings: 10-K · 10-Q